1 This study, involving eight healthy volunteers, revealed that food intake does not have a clinically significant effect on vigabatrin kinetics. 2 Kinetics of vigabatrin in the fasting state showed low inter-individual variation. 3 The plasma concentration vs time profile followed a bi-exponential decline with a terminal half-life of 6.8 h and a relative bioavailability of 92% ± 11%. 4 In the clinical setting, vigabatrin may be taken at times convenient for the patient.
Summary:We describe an improved procedure using a standard microplate immunoassay reader to measure the concentration of troponin T in human serum. We also describe an immunoassay for troponin I in serum. Only 160 μΐ of serum are needed for a single analysis of each troponin. For comparison, creatine kinase MB mass analysis in serum was performed with a commercial luminometric method. From 95 apparently healthy people the following values were obtained: creatine kinase MB mass 2.6 ±1.2 μg/l, troponin Τ 0.027 ± 0.025 μg/l and troponin I 0.03 ± 0.031We compared the results of troponin Τ and troponin I methods with each other, as well as with those of creatine kinase MB mass measured in 48 patients with verified acute myocardial infarction and in 60 control patients with non-cardiac chest pain. The correlation between troponin Τ and troponin I values was 0.91 for the total material and 0.94 for 48 patients with acute myocardial infarction. Troponin I showed better earlier sensitivity than troponin Τ (ρ = 0.043). In nine patients in the control group, creatine kinase MB mass exceeded the reference limit of 5.0 μg/l, while in two patients the cut-off limit of 10.0 μ §/1 was also surpassed, pointing to non-specificity.In the group of infarct patients, the highest serum creatinine value was 193 μηιοΐ/ΐ, whereas in the control group it was 406 μιηοΙ/1. The sera of patients with impaired renal function without any cardiac failure showed no increase in troponin Τ and troponin I values.In conclusion, serum creatine kinase MB mass and troponin I seem to confirm an acute myocardial infarction more rapidly than does troponin T; troponin I has the highest cardiac specificity.
The cardiovascular effects and the pharmacokinetics of a new selective alpha-2 adrenoceptor antagonist, benalfocin, and its active metabolite, both compounds with a similar receptor affinity profile, were examined in healthy volunteers during repeated dosage. Significant diastolic blood pressure lowering effects were observed on the first and the last day of the treatment persisting throughout the dosage interval. Furthermore, heart rate reductions were found on these days which were significantly correlated with both the parent compound's and the metabolite's plasma concentrations and their sum. Pharmacokinetics remained unchanged after a 1-wk oral dosing as compared to a single oral dose; the plasma half-life of the metabolite was 3-fold longer than that of the parent compound. In normotensive subjects, benalfocin produced blood pressure and heart rate reducing effects, the latter being more correlated with the metabolite's plasma concentrations. Furthermore, results suggest that the compound's known cholinergic effects may be particularly related to the metabolite and that this molecule is an interesting cardiovascular compound.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.